Business Wire

FPT Proposes Public-Private Partnership Model to Develop Vietnam’s Digital Healthcare Ecosystem

10.6.2025 07:17:00 EEST | Business Wire | Press release

Share

Global IT services provider FPT and Pharma Group jointly hosted the Healthcare Innovation Forum - HIF 2025. The event served as a multi-stakeholder dialogue platform with a spotlight on breakthrough innovations in science, technology, and AI to accelerate healthcare advancements and drive digital transformation in public health services.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609760138/en/

FPT Proposes Public-Private Partnership Model to Develop Vietnam’s Digital Healthcare Ecosystem

The Forum was attended by Vietnam Deputy PM H.E. Le Thanh Long, key government officials, and international guests including U.S. Ambassador Marc Knapper, Swiss Ambassador Thomas Gass, former German Vice Chancellor Dr. Philipp Rösler, and representatives from Japan, Singapore, and Harvard Medical School.

Vietnam Deputy PM H.E. Le Thanh Long stressed the urgent need to reform healthcare, outlining five strategies: accelerate digitalization with AI and IoT; boost biotech research; strengthen the pharmaceutical sector; foster public–private partnerships; and expand international cooperation for a modern digital health system.

Mr. Darrell Oh, Chairman of Pharma Group, said: “Pharma Group, representing the innovative pharmaceutical industry, reaffirms its commitment to supporting Vietnam in achieving the goals outlined in Vision 2045. Realizing this ambition requires a unified, multi-stakeholder approach. Only through sustained collaboration can policy be translated into impactful, lasting improvements in public health. Investing in healthcare is, ultimately, an investment in Vietnam’s most vital asset: its people.”

Dr. Truong Gia Binh, FPT Chairman, stated: “To accompany Vietnam’s new era of advancement, the healthcare sector must achieve breakthroughs in three areas: regulation, innovation, and public–private collaboration. We must shift from restrictive thinking to viewing regulation as a driver of national competitiveness, ensuring faster access to new medicines, like in the U.S. or Japan. Vietnam can become a hub for AI-powered clinical trials and drug development, leveraging its strong tech talent with 1 million IT workers, aiming for half to be AI-proficient. Public–private partnerships must connect hospitals, pharmaceutical firms, and healthcare professionals through shared data platforms. Just as Vietnam rose to global prominence in software, it can now aim to lead in innovative pharmaceuticals - one of the world’s most advanced industries.”

AI in Pharma: A Global Trend and an Opportunity for Vietnam

Recent data shows 80% of pharma professionals use AI for drug discovery, with 95% of companies investing in it; and AI can cut drug development time from 5-6 years to one. In clinical trials, AI can reduce costs by 70% and timelines by 80%.

Mr. Hoang Viet Anh, FPT Digital Chairman and FPT Telecom Chairman, FPT Corporation, underscored: “AI and GenAI are transforming the pharmaceutical industry, with key benefits including accelerating new drug development and enhancing clinical trials across the value chain.” He also called this a key moment for digital transformation, outlining an AI roadmap for Vietnam’s pharmaceutical sector through 2028. Plans include a centralized data system and AI lab pilots in 2025, blockchain trials in 2026 to fight counterfeit drugs, and a 20% reduction in drug trial time by 2027, aiming to become ASEAN’s leading AI hub by 2028.

Achieving Resolution 57 and National Goals for Healthcare Breakthroughs

As Vietnam pursues its 2045 high-income vision, healthcare emerges as a key pillar for quality of life, social security, and sustainable growth. The round table discussing critical factors to achieve Resolution 57 objectives emphasized three key messages. Firstly, AI and big data drive healthcare innovation, enabling faster drug development and personalized care. Secondly, bold legal and institutional reforms are essential to match tech advances, including streamlined approvals and flexible data regulations. Lastly, strong public-private collaboration is vital to build a sustainable innovation ecosystem connecting tech firms, hospitals, research institutes, and startups.

Mr. Vu Anh Tu, FPT Chief Technology Officer, commented: “AI is set to transform healthcare, and by creating a centralized health data infrastructure and leveraging AI and data analysis for new drug trials, Vietnam can establish advanced clinical research centers, shorten timelines, reduce costs, and expand public access to new medicines. Technology can also enable new healthcare delivery models like telemedicine hospitals to improve primary healthcare and expand public access.”

He further stated: “FPT is ready to collaborate with startups, major enterprises, and global AI research institutions to address key challenges through AI. This approach will mobilize domestic and international resources to drive breakthroughs in this new era.”

About Pharma Group

Founded in 1998, Pharma Group represents the innovative pharmaceutical industry in Vietnam, comprising 20 member companies from Europe, the United States, and Japan. These companies share a mission to ensure timely and sustainable access to high-quality, safe, and innovative medicines for Vietnamese patients.

Pharma Group operates under the European Chamber of Commerce in Vietnam (EuroCham) and is a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). It works closely with policymakers and healthcare stakeholders in Vietnam and globally to advance sustainable health policies and initiatives, reduce the time to patient access, and build a favorable and attractive investment environment.

About FPT Corporation

FPT Corporation is Vietnam’s leading technology group, pioneering digital transformation and leading in technology and telecommunications solutions and services. FPT supports clients in over 30 countries and territories in achieving their business development strategies through technology.

In the healthcare sector, FPT is committed to building a remote healthcare platform and a comprehensive digital medical ecosystem that delivers fast, convenient, and integrated services for regulators, medical institutions, pharmaceutical companies, pharmacy networks, and the public. Leveraging over a decade of AI research and development, FPT actively integrates AI technologies to enhance healthcare quality and expand access to personalized medical services, particularly through telemedicine and real-time patient health monitoring. In pharmaceuticals, FPT advances the sector by digitizing R&D processes, deploying Advanced Pharmacy Omni-Channel Systems, and developing comprehensive drug management platforms connecting patients, doctors, and pharmacies through electronic medical records. Prominent clients include Long Chau Pharmacy, Hitachi Medical Devices, Olympus, MedAdvisor, Zuellig Pharma, and BrightInsight.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250609760138/en/

Contacts

Media Contact
Mai Duong (Ms.)
FPT Corporation
FPT Software PR Manager
MCP.PR@fpt.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 10:00:00 EEST | Press release

SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter timeframes. The MoU underscores growing market adoption of SWISSto12’s HummingLink payload technology that leverages 3D-printing, with more than 2,000 pr

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 10:00:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly effective oral therapies that also address the diverse and often challenging manifestations of psoriasis, including involvement of high-impact sites like the scalp,” said Andy Plump, M.D., Ph.D., president of R&D at Takeda. “Our Phase 3 data demonstrated rapid and durable skin clearance across various patient types and in high-impact and hard-to-treat areas. Based on the results across nearly 3,000 patients, zaso

Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 10:00:00 EEST | Press release

According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, today announced the launch of Luna 8, its next-generation hardware security module. Designed for the transition to post-quantum cryptography, Luna 8 enables organizations to securely store, protect, and manage cryptographic keys with market-leading performance, scalability, and speed. As organizations face growing pressure from emerging quantum threats, expanding AI workloads and evolving stringent regulatory requirements, Luna 8 provides the performance, security and cryp

Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 08:00:00 EEST | Press release

Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participants. This allows those platforms to interoperate with traditional Link-16 platfor

Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 08:00:00 EEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye